A clinical trial of avapritinib versus regorafenib (Stivarga®) for people with advanced GIST that has progressed following first-line treatment with imatinib (Gleevec®) and one or two additional treatment regimens (third-line or fourth-line GIST).
The Moffitt Cancer Center advances personalized medicine and using predictive modeling to anticipate – and change – a tumor’s path. By exploring genomics, immunotherapy and more, Moffitt Cancer Center is at the very forefront of cancer centers worldwide in pioneering advances like CAR T-cell therapy, a promising approach to immunotherapy that uses a patient’s own immune cells to recognize and attack their tumors.
Tampa, Florida Clinical Trial Location
Moffitt Cancer Center
12902 USF Magnolia Drive,
Tampa, FL 33612